ReviewExperimental biology and medicine (Maywood, N.J.)2023
Wogonin, as a potent anticancer compound: From chemistry to cellular interactions.
Review in Experimental biology and medicine (Maywood, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy.Life (Basel, Switzerland) · 2026Review
- Integrative systems biology identifies PSMB2 as a core oxidative stress-associated target in triple-negative breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Targeting the gut-ovarian axis:mSystems · 2026Article
- Wogonin as a potential therapeutic agent for psoriasis: Core target identification and validation.Experimental and therapeutic medicine · 2026Article
- Pyroptosis Regulated by N6-Methyladenosine Modification: Implications for Pyroptosis-Related Disease Therapy.Journal of innate immunity · 2026Review
- Wogonoside alleviates ulcerative colitis-induced senescence by activating AMPK inAmerican journal of translational research · 2026Article
- Bioactive Flavonoids fromDrug design, development and therapy · 2026Review
- Anticancer Potential of Wogonin: A Comprehensive Treatise.Food science & nutrition · 2025Review
- Dynamics of epithelial-mesenchymal plasticity driving cancer drug resistance.Cancer pathogenesis and therapy · 2025Review
- Wogonin suppresses proliferation, invasion and migration in gastric cancer cells via targeting the JAK-STAT3 pathway.Scientific reports · 2024Article
- Revealing the mechanism of natural product-induced immunogenic cell death: opening a new chapter in tumor immunotherapy.Frontiers in immunology · 2024Review
- Molecular mechanism of Achyranthis bidentatae radix and Morindae officinalis radix in osteoporosis therapy: An investigation based on network pharmacology, molecular docking, and molecular dynamics simulations.Biochemistry and biophysics reports · 2023Article
- Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal models.Journal of cancer research and clinical oncology · 2023Review
- The Pharmacological Implications of Flavopiridol: An Updated Overview.Molecules (Basel, Switzerland) · 2023Review
- Research Progress ofIntegrative cancer therapiesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chinese native medicine
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.